Experimental allergy combo aims to shut down allergic reactions at the source

NCT ID NCT06369467

First seen Nov 16, 2025 · Last updated May 16, 2026 · Updated 18 times

Summary

This early-phase study tests an experimental drug, linvoseltamab, combined with dupilumab in 6 adults with severe food allergies (like peanut or milk) that can cause life-threatening reactions. The goal is to see if the combo is safe and how it affects IgE antibodies, which drive allergic responses. Participants must have a history of anaphylaxis requiring epinephrine or emergency care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinica Universidad de Navarra - Madrid

    WITHDRAWN

    Madrid, 28027, Spain

  • Clinica Universidad de Navarra- Pamplona

    WITHDRAWN

    Pamplona, Navarre, 31008, Spain

  • Emory University - Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • The Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University of South Florida

    RECRUITING

    Tampa, Florida, 33613, United States

Conditions

Explore the condition pages connected to this study.